Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
Novo Nordisk NVO recently launched Awiqli (insulin icodec-abae) in the United States, introducing the first once-weekly basal insulin for…
Novo Nordisk tests first Japan obesity referral model in Aichi
KEY POINTSNovo Nordisk Pharma and Kasugai test Japan’s first obesity referral model from health checks to specialist careAll…
Pursuing patient options, Novo kicks off trial testing smaller doses of Wegovy pill
Just eight months after it introduced its oral version of semaglutide for obesity, also known as the Wegovy…
How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
Eli Lilly LLY remains a dominant player in the GLP-1 market, led by Mounjaro for type II diabetes (T2D)…
Pfizer’s Obesity Push: Can Berobenatide Take Market Share?
The global obesity market is emerging as one of the largest growth opportunities in pharmaceuticals. The market is…
How Does LLY’s Q2 GLP-1 Portfolio Performance Stack Up Against NVO’s?
Eli Lilly LLY remains a dominant player in the GLP-1 market, led by Mounjaro for type II diabetes (T2D)…
Novo Nordisk runs new obesity experience installation in London
Novo Nordisk is running an exhibition in central London designed to start a dialogue on obesity and help…
Obesity not a ‘zero-sum game’ as patients crave optionality, Novo CEO says: Reuters
Pushing back on the concept that there can only be one victor among branded obesity drugmakers, Novo Nordisk…
Eli Lilly vs. Novo Nordisk: Has GLP-1 Manufacturing Become the New Competitive Moat?
The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have…
Novo Nordisk Swallows the Bitter Pill
Novo Nordisk Swallows the Bitter Pill – Moby THE GIST Our analysts just identified a stock with the…
Novo Nordisk Before Q2 Earnings: How Should Investors Play the Stock?
Novo Nordisk NVO is scheduled to report its second-quarter 2026 results on Aug. 5, 2026, before the opening bell.…
Obesity battle heats up again as Novo claws its way back into race with Lilly
London – Novo Nordisk investors have found little cause for optimism during a bruising two-year period of profit…